Scientific Programme

IMPORTANT LINKS / DOWNLOADS


The 13th World Conference on Lung Cancer will highlight recent important advances in lung cancer in the areas of prevention, early detection, molecular biology, biotechnology and therapy.

ePOSTERS ONSITE


Papers discussed in Poster Discussion Sessions are presented as ePosters. Click here to get access to the ePoster online viewing system. Enjoy!
Presenting authors should register with the username and password that they used to submit the ePosters. Only by using this username and password they will be able to see any comments that delegates have sent them through the ePoster system!

PERSONAL ITINERARY BUILDER (INCL. ABSTRACTS)


Attendees are invited to create their own conference programme by utilizing the Personal Itinerary Builder. The Personal Itinerary Builder allows you to search for all abstracts submitted to the 13th WCLC. Intelligent search functions help finding any abstract within seconds. You can search by session, moderator, author or topic. In order to build your personal itinerary (your programme at a glance), create your own account first and then simply click on the respective sessions you wish to attend to add them to your personal programme.

Once you have finished putting your programme together, a PDF file will be created which you may either print or save to your computer. You may return to your programme whenever you want. Re-enter with your password and you'll always find the latest version of your itinerary.

Click here to get access to the Personal Itinerary Builder!

We hope you will find this tool useful and appreciate your comments!

 

SCIENTIFIC PROGRAMME


Final Scientific Programme as of 10 July 2009 (print date) (PDF 4 MB)

FRIDAY 31 JULY

07:00 – 11:00    YOUNG INVESTIGATOR'S SESSION
Chairs: Silvia Novello, Italy; Heather Wakelee, USA

The Future of Lung Cancer: Better Detection, Better Targeting
Better Detection
1) Finding the Lung Cancer Stem Cell - John Minna, USA
2) Improvements in Early Detection - James Jett, USA
3) New Imaging Tools for Diagnosis and Therapy Monitoring in Lung Cancer - Homer Macapinlac, USA
4) Non-invasive Mediastinal Staging - Stefano Gasparini, Italy

Better Targeting
5) Gene Expression Profiling for Diagnosis and Therapy - Anil Potti, USA
6) Pharmacogenomic based Strategies for Diagnosis and Therapy - Louis Paz-Arez, Spain
7) Biomarkers for Targeted Agents - John Heymach, USA
8) Trials Designs for Biomarker Assessment - Lucinda Billingham, UK

11:00 - 13:00   Boehringer-Ingelheim Satellite Symposium:
  New + Emerging Strategies for Targeting Non-Small Cell Lung Cancer
13:30 - 15:30 The PESG Symposium
  Subdividing NSCLC: Is It Now Multiple Diseases? Supported by an independent educational grant form Eli Lilly and Company
15:45 - 17:45 Covidien Satellite Symposium:
  Optimizing Care of the Patient with Early Stage Lung Cancer
 
18:00 – 19:30    OPENING CEREMONY
 
19:30 – 21:00    WELCOME RECEPTION

 

SATURDAY 1 AUGUST

07:00 - 08:00 Bristol-Myers Squibb Satellite Symposium:
  Zeroing in on Lung Cancer: Integrating Targeted Therapies into Practice
 
07:00 – 08:00    MEET THE PROFESSOR SESSIONS
Medical Oncology
MTP1 Lung Cancer Vaccines – Glen Goss, Canada
MTP2 Novel Therapies Improving Toxicities and Side Effects in Thoracic Radiation – Umberto Ricardi, Italy
Pulmonary
MTP3 Interventional Bronchoscopic Techniques in The Treatment of Lung Cancer - Thomas Sutedja, Netherlands
Biology
MTP4 Preneoplasia of Lung Cancer - Adi Gazdar, USA
MTP5 Oncopolitics - James Mulshine, USA
Pathology
MTP6 Large Cell Carcinoma - Keith Kerr, UK
Surgery
MTP7 Maximizing Perioperative Outcome after Neoadjuvant Therapy - Stephen Swisher, USA
Supportive Care
MTP8 Comprehensive Pain Management in the Advanced Lung Cancer Patient
CANCELLED
Radiation Oncology
MTP9 Thoracic Radiotherapy in Small Cell Lung Cancer - Andrew Turrisi, USA
Imaging
MTP10 After pemetrexed and cisplatin, what is the way forward? - Nicholas Vogelzang, USA
   
08:30 – 10:00    PLENARY SESSION
PL1 Personalized Therapy
  Chairs: David Gandara, USA; Joseph Nevins, USA
 
  • Overview – David Gandara, USA
  • Biomarker Development: Muddy Waters – Harvey Pass, USA
  • Emerging Methodologies – Fred Hirsch, USA
  • Genomic Strategies for Personalized Therapy – Joseph Nevins, USA
  • Pharmacogenomic Approaches - Giorgio Scagliotti, Italy
   
09:30 - 17:30 POSTER DISPLAY
P1

Basic Science and Translational Research
Cancer Control and Epidemiology
Health Services Resources
NSCLC Advanced Disease
Tobacco Control

Poster Presentations (pdf) updated 13 July

   
10:30 – 12:00    INTERACTIVE GRAND ROUNDS SESSION
GR1 Stage IIIA N2: 2003 versus 2009
  Participants: Paul Van Houtte, Belgium; Eric Vallieres, USA; Kathy Albain, USA
   
10:30 – 12:00   EDUCATION AND MINI SYMPOSIA SESSIONS
Medical Oncology
E1 EGFR Pathway
  Chairs: Mark Kris, USA; Alex Yuang-Chi Chang, Singapore
 
  • Using Biomarkers to Predict Response to EGFR Inhibitors – Mark Kris, USA
  • Biology of the EGF Pathway – Yosef Yarden, Israel
  • Using Biomarkers to Predict Response to EGFR Inhibitors - Mark Kris, USA
  • Management of Toxicities of Anti-Angiogenic/Anti-EGFR agents – Roman Perez-Soler, USA
  • State of the Art of Clinical Research with Monoclonal Antibodies – Jean-Yves Douillard, France
M1 Novel Targets Beyond EGFR and VEGFR
  Chairs:Sarita Dubey, USA; Giuseppe Giaccone, USA
 
  • Src as a Target - Dean Fennell, UK
  • m-Tor Inhibitors - Lucio Crino, Italy
  • HSP Inhibitors - Kenneth O’Byrne, Ireland
  • HDAC Inhibitors - Lee Krug, USA
  • Pro-apoptotic Agents - Rolf Stahel, Switzerland
Pulmonary
E2 Minimally Invasive Non-Surgical NSCLC Staging
  Chairs: Michael Alberts, USA; Stefano Gasparini, Italy
 
  • The Merits of Traditional Bronchoscopic Transbronchial Needle Aspiration - Stefano Gasparini, Italy
  • The Advantages of Endobronchial Ultrasound Guided Needle Aspiration - Heinrich Becker, Germany
  • Endoscopic Ultrasound Guided Needle Biopsy: Complementary or First Line? - Louis Irving, Australia
  • Electromagnetic Navigation Guided Biopsy of Mediastinal Lymph Nodes. The Latest Technology - Felix Herth, Germany
Biology
E3 Future Directions in Lung Cancer Chemoprevention
  Chairs: Ugo Pastorino, Italy; James Mulshine, USA
 
  • PPARgamma as a target for Aerodigestive Chemoprevention - Frank Ondrey, USA
  • The Balance Between Cell Survival and Cell Death in Lung Cancer Chemoprevention - Shi-Yong Sun, USA
  • Emerging Models for Lung Carcinogenesis - Luis Montuenga, Spain
M2 Angiogenesis in Lung Cancer
  Chairs: Christian Manegold, Germany; Alan Sandler, USA
 
  • Tumor Hypoxia, Angiogenesis and Lung Cancer - Joan Schiller, USA
  • Predictive Plasma Biomarker Profiles - Suresh Ramalingam, USA
  • Therapeutic Combinations with Bevacizumab - Antoinette Wozniak, USA
  • Role of Anti-Angiogenic TKI’s - Heather Wakelee, USA
  • Clinical Factors in Selecting Patients for Anti-Angiogenic Therapy - Alan Sandler, USA
Pathology
M3 Pathological Diagnosis and Molecular Analysis of Small and Cytological Specimens
  Chairs: Kim Geisinger, USA; Elisabeth Brambilla, France
 
  • Histopathological Diagnosis on Frozen Examination - Lucian Chirieac, USA
  • FNA Diagnosis - Getting the most out of it - Lukas Bubendorf, Switzerland
  • Assessment of Cytological Samples - Maureen Zakowski, USA
  • Gene Copy Number and Genetic Instability - Iver Petersen, Germany
  • Assessment of Invasion Before Surgery - Alain Borczuk, USA
Radiation Oncology
E4 Preclinical and Translational Studies in Lung Cancer Radiotherapy
  Chairs: David Raben, USA; Michael MacManus, Australia
 
  • Aurora Kinase Inhibitor + Radiation for NSCLC - Bo Lu, USA
  • Src Kinase Inhibition and Radiation in NSCLC - David Raben, USA
  • PARP Inhibition and Tumour Radio Sensitivity – Ian Stratford, UK
  • Imaging with 18F-3-deoxy-3-fluoro-l-thymidine (FLT) positron emission tomography in patients with lung cancer - Michael MacManus, Australia
Prevention
E5 Targets for Chemoprevention
  Chairs: Nico van Zandwijk, Australia; Ignacio Wistuba, USA
 
  • Inflammatory Proteins - Eva Szabo, USA
  • IGF-1R Pathway - Fadlo Khuri, USA
  • Chemoprevention: EGFR Targeted Agents  - York Miller, USA
  • COX/LOX Inhibition -Jenny Mao, USA
M4 Tobacco Control
  Chairs: Carolyn Dresler, USA; Janine Cataldo, USA
 
  • Challenges of Tobacco Control in the US - Stanton Glantz, USA
  • Tobacco Control Strategies in Europe - John Britton, UK
  • Tobacco Epidemic and Tobacco Control in China - Xiuyi Zhi, China
  • Tobacco Control in South America - Nise Yamaguchi, Brazil
  • Smoking Cessation in Asia - Jin Soo Lee, South Korea
Supportive Care
M5 Controlling Adverse Effects of Treatment in Lung Cancer
  Chairs: Paul Hesketh, USA; Tomoya Kawaguchi, Japan
 
  • Mucositis and Lung Cancer - Dorothy Keefe, Australia
  • Emesis - Steven Grunberg, USA
  • Fatigue in SNCLC: Etiology, Impact and Treat Options - John Eckhardt, USA
  • Cutaneous Toxicities - Mario Lacouture, USA
Surgery
E6 Optimal Therapy for Resectable Lung Cancer
  Chairs: Jack Roth, USA; Riad Younes, Brazil
 
  • Neoadjuvant Chemotherapy - Steven Keller, USA
  • Adjuvant Chemotherapy - Nasser Hanna, USA
  • Pharmacogenomic Approaches - Rafael Rosell, Spain
  • Predictive Markers - David Harpole, USA
Imaging
E7 Early Detection of Lung Cancer
  Chairs: Johan Vansteenkiste, Belgium; Rob van Klaveren, Netherlands
 
  • Current Screening Trial Results - James Jett, USA
  • Evaluation of Indeterminate Pulmonary Nodule/GGO - Yasuo Nakajima, Japan
  • Ancillary Findings on Screening Studies - Stephen Swensen, USA
   
12:15 - 14:15 The Center for Biomedical Continuing Education Satellite Symposium:
  Defining the Optimal Therapeutic Sequence for Patients with NSCLC: Molecular and Clinical Considerations
 
12:15 - 14:15 POSTER DISPLAY / AUTHOR STAND BY TIME
 
14:30 – 16:00    GLOBAL LUNG CANCER COALITION SYMPOSIUM
   
14:30 – 16:00    PROFFERED PAPER AND POSTER DISCUSSION SESSIONS
  Proffered Paper Sessions (pdf) updated 16 July
  Poster Discussion Sessions updated 16 July
   
16:30 – 18:00    INTERACTIVE GRAND ROUNDS SESSION
GR2 Adjuvant Chemotherapy: Stage Specific Discussion
  Chairs: Thierry Le Chevalier, France; James Bishop, Australia
  Participants: Mark Socinski, USA; Raymond Abratt, South Africa; Joseph Putnam, USA
   
16:30 – 18:00    EDUCATION AND MINI SYMPOSIA SESSIONS
Medical Oncology
E8 VEGF pathway
  Chairs: Christian Manegold, Germany; Philip Bonomi, USA
 
  • History of Anti-Angiogenesis-based therapies in the treatment of NSCLC – Philip Bonomi, USA
  • State of the Art of Clinical Research with Monoclonal Antibodies - David Johnson, USA
  • State of the Art of Clinical Research with Small VEGF-TKI Molecules - Thierry Jahan, USA
  • Management of Toxicities of Anti-Angiogenic/Anti-EGFR agents - John Heymach, USA
M6 Established Targets for NSCLC-  Multi-Targeted Agents and Drug Combinations
  Chairs: Roy Herbst, USA;  Kazuhiko Nakagawa, Japan
 
  • Multiple Tyrosine Kinase Inhibitors : What is the Rationale and the Clinical Evidence? - Chandra P. Belani, USA
  • IGF1R Pathway : Rationale and Inhibitors – Ross Camidge, USA
  • ASA404, A Novel Tumor Vascular Disrupting Agent (VDA): Rationale for Advanced Non-Small Cell Lung Cancer Therapy – Primo Lara, USA
  • Emerging EGFR biomarkers - Thomas Lynch, USA
  • DNA Repair Mechanisms to Tailor Therapy in NSCLC- Jean Charles Soria, France
M7 Progress with Neoadjuvant Window of Opportunity Trials
  Chairs: Vaseilios Georgoulias, Greece; Purvish Parikh, India
 
  • Clinical Results - Nasser Altorki, USA
  • Standardizing Acquisition Parameters and Imaging Quality -David Yankelevitz, USA
  • Development of Image Processing Tools for Drug Response Evaluation - Rick Avila, USA
  • NeoAdjuvant Trial with RAD001 - Fadlo Khuri, USA
  • Challenges of Neoadjuvant Window of Opportunity Trials - Purvish Parikh, India
E9 Neoadjuvant Chemotherapy Trials in Lung Cancer
  Chairs:  Alain Depierre, France; Martin Edelman, USA
 
  • Neoadjuvant Chemotherpay Past and Present US Trials – Martin Edelman, USA
  • Neoadjuvant Chemotherapy Past and Present European Trials - Bernard Milleron, France
  • S9900 Trial Update, Mature Analysis - Katherine Pisters, USA
  • Surgical Issues with Neoadjuvant Trials- Is the Surgical Risk Increased? - Kemp Kernstine, USA
Pulmonary
M8 Novel Technologies
  Chairs: Paul Germonpre,Belgium; Haruhiko Nakamura, Japan
 
  • Early Detection of Lung Cancer using an Electronic Nose - Annette McWilliams, Canada
  • Optical Coherence Tomography - Stephen Lam, Canada
  • Autofluorescence-Reflectance Imaging - Norihiko Ikeda, Japan
  • Narrow band imaging is a new investigatory tool to visualize angiogenesis in squamous cell carcinoma of the lung - Kiyoshi Shibuya, Japan
  • Confocal Micro-Endosocopy - Luc Thiberville, France
Biology
M9 Predictive or Prognostic Factors in Chemotherapy
  Chairs: Rafael Rosell, Spain; Bruce Johnson, USA
 
  • ERCC1 and RRM1 – Predictive vs. Prognostic Roles - George Simon, USA
  • BRCA1 Gene and Sensitivity to Lung Cancer Chemotherapy - Rafael Rosell, Spain
  • Thymidylate Synthase as a Marker of Sensitivity to Anti-Folates - Giorgio Scagliotti, Italy
  • KRAS as a Marker of Chemoresistance - Ming Tsao, Canada
  • Genomic Strategies to Guide Standard Chemotherapy - Joseph Nevins, USA
Surgery
M10 Emerging Operative Techniques in Early Stage Lung Cancer
  Chairs: Xiu-Yi Zhi, China; Shaf Keshavjee, Canada
 
  • Techniques of VATS Resections for Lobectomy, Segmentectomies, and Lymph Node Dissections and Their Results in 2009: Who are the Candidates, When Do You Not Do This? - Thomas D’Amico, USA
  • Evidence for the Use of Sublobar vs Lobar Resections for the Medically Operable Lung Cancer Patient: A Complete Review of the Literature with Most Recent Results - Shun-ichi Watanabe, Japan
  • Intraoperative Techniques for the Prevention of Positive Margins - Sue Yom, USA
  • Management of the Patient with Multiple Synchronous/Metachronous Pulmonary Lesions: Lobectomies, Segmentectomies, Wedge Resections, Simultaneous, Staged, How much Staging? -  Kenji Suzuki, Japan
Prevention
M11 Women and Lung Cancer
  Chairs: Laurie Gaspar,USA; Enriqueta Felip, Spain
 
  • Smoking Cessation Strategies in Women - Carolyn Dresler, USA
  • Genetic Susceptibility to Lung Cancer in Women - Julie Brahmer, USA
  • Estrogen and Progesteron Receptors in Lung Cancer - Jill Siegfried, USA
  • Sex as a Prognostic and Predictive Factor - Silvia Novello, Italy
  • Clinical and Epidemiologic Features of Lung Cancer in Asian Females - Sumitra Thongprasert, Thailand
Radiation Oncology
M12 Debate - Stereotactic Radiotherapy for Stage I NSCLC: Should itbe Regarded as the Standard of Care for Inoperable Tumors and Are We Ready to Replace Surgery?
  Chairs: Robert Timmermann, USA; David Ball, Australia
 
  • For STR in Inoperable Tumor - Robert Timmermann, USA
  • Against SRT in Inoperable Tumors – David Ball, Australia
  • For STR in Operable Tumors – Suresh Senan, Netherlands
  • Against SRT in Operable Tumors – Paul van Schil, Belgium
Imaging
M13 Staging and Follow-up of Lung Cancer
  Chairs: David Shelton, USA; Ken Yoneda, USA
 
  • Conventional Imaging (CT, MR) - Ann Leung, USA
  • CT/PET Staging - Jeremy Erasmus, USA
  • Endoscopic Ultrasound (EBUS-EUS) for staging and follow up of lung cancer -  Kazuhiro Yasufuku, Canada
  • Imaging Response and Surveillance (PET, CT) - Homer Macapinlac, USA
  • Molecular Diagnostics and New Imaging Probes - Ramsey Badawi, USA
Mesothelioma
M14 New Insights in the Pathogenesis and Treatment of Malignant Mesothelioma
  Chairs: Raja Flores, USA; Nicholas Vogelzang, USA
 
  • The Asbestos Threat: A World-Wide Overview of the Epidemiology of Asbestos Exposure - Ken Takahashi, Japan
  • Non-Asbestos Related Mesothelioma: The Role of SV40 - Michele Carbone, USA
  • Current MM Lab Studies and their Possible Translation - Robert Kratzke, USA
  • Gene Therapy/Immunotherapy and Mesothelioma: Where Are We - Steven Albelda, USA
Biostatistics
M15 Statistical Issues in Drug Development
  Chairs:  John Crowley, USA;  Mary Redman, USA
 
  • Phase I and II Strategies for Choosing a Good Dose with Targeted Agents - John Crowley, USA
  • Phase I Designs for Identifying a Blologically Optimal Dose - Sumithra Mandrekar, USA
  • Dose Escalation Trials Based on a Molecularly Targeted Endpoint - Sally Hunsberger, USA
  • A Clinician's Perspective - Derick Lau, USA
   
18:30 - 20:30 Merck KGaA Satellite Symposium
  Taking the Next Step to Improve the Treatment of NSCLC

 

SUNDAY 2 AUGUST

07:00 - 08:00 Biodesix Satellite Symposium:
  Advances in EGFR Inhibitor Biomarkers
07:00 - 08:00 Response Genetics:
  Personalized Medicine. Predictive Biomarkers in Clinical Practice.
   
07:00 – 08:00    MEET THE PROFESSOR SESSIONS
Medical Oncology
MTP11 Bevacizumab Dosing and Duration - Christian Manegold, Germany
MTP12 Novel Cytotoxics in Small Cell Lung Cancer – Vera Hirsh, Canada
MTP13 Systemic Treatment of Brain Metastasis in Lung Cancer - Corey Langer, USA
Pulmonary
MTP14 Management of Malignant Pleural Effusions -  Philippe Astoul, France
Pathology
MTP15 Mesothelioma - Kirk Jones, USA
Biology
MTP16 Novel Signal Transduction Pathways - Giuseppe Giaccone, USA
MTP17 Molecular Biology and Pathology of Lung Adenocarcinomas - Yasushi Yatabe, Japan
Radiation Oncology
MTP18 Management of Oligometastasis: Should Patients with Limited Sites of Metastasis be Treated Aggressively? - Andrea Bezjak, Canada
MTP19 Current Status of Prophylactic Cranial Irradiation in SCLC - Cecile Le Pechoux, France
Mesothelioma
MTP20 Translational Research and Mesothelioma - Harvey Pass, USA
Supportive Care
MTP21 Neurological Complications of Lung Cancer and its Treatment - Jerome Posner, USA
   
08:30 – 10:00    PLENARY SESSION
PL2 State of the Art
  Chairs:  Frances Shepherd, Canada; Masahiro Tsuboi, Japan
 
  • Surgery Masahiro Tsuboi, Japan
  • Radiotherapy – Hak Choy, USA
  • Chemotherapy – Everett Vokes, USA
  • Targeted Therapy for Non-Small Cell Lung Cancer – Frances Shepherd, Canada
   
09:30 - 17:30 POSTER DISPLAY
P2

Endoscopy and Intervention Bronchoscopy
Imaging
Mesothelioma, Thymoma and Others
Non-Small-Cell Lung Cancer - Early Disease
Novel Therapeutics and Modalities
Pulmonary Medicine
Small Cell Lung Cancer
Surgery

Poster Presentations (pdf) updated 16 July

   
10:30 – 12:00    INTERACTIVE GRAND ROUNDS SESSION
GR3 Testing for Biomarker driven Therapy (ERCC1 and EGFR)
  Participants: Gerold Bepler,USA; Vincent Miller,USA; Janet Dancey, Canada
   
10:30 – 12:00    HIGHLIGHT OF THE DAY SESSION
HOD1 HIGHLIGHT OF THE DAY
  David Ettinger, USA
   
10:30 – 12:00    EDUCATION AND MINI SYMPOSIA SESSIONS
Medical Oncology
M16 Clinical Trial Designs with Biomarkers to Incorporate or Validate Clinical or Lab Selection
  Chairs: John Crowley, USA; Elisabeth Quoix, France
 
  • Front Line Studies Using Clinical Parameters for EGFR-TKIs  - Tony Mok, Hong Kong
  • Epidermal growth factor receptor assessment in prospective studies – Rafal Dziadziusko, Poland
  • How to Design a Meta-Analysis in Biomarkers - Lucinda Billingham, UK
  • Prospective Studies with Proteomics – Vanesa Gregorc, Italy
  • Histology As A Selection Factor for Treatment – Shirish Gadgeel, USA
Pulmonary
E10 Management of Malignant Pleural Effusions
  Chairs: Philippe Astoul, France; John Beamis, USA
 
  • Surgical Management of Malignant Pleural Effusions - Raja Flores, USA
  • Thoracoscopy - John Beamis, USA
  • PleurX Catheter Placement - Alain Tremblay, Canada
  • Implanted Port Reservoir for Pleural Drainage – Ken Yoneda, USA
Biology
E11 Genetics and Epigenetics in Lung Carcinogenesis
  Chairs: Ravi Salgia, USA; Adi Gazdar, USA
 
  • DNA Methylation Markers in Lung Cancer - Sabine Zöchbauer-Müller, Austria
  • Somatic Mutations in Lung Cancer - Monserrat Sanchez-Caspedes, Spain
  • Molecular Changes in Invasion, Tumor Progression and Metastasis - Wilbur Franklin, USA
M17 Identifying Cancer Stem Cells
  Chairs: David Jablons, USA; Nobuyuki Yamamoto, Japan
 
  • Stem Cell Population in Mouse Lung Cancer - Allan Balmain, USA
  • Prognostic Markers                                                             
      • Wnt Pathway in Lung Cancer - Liang You, USA
      • The Hedgehog signaling pathway in lung cancer: moving beyond inhibition of cell growth - Rajat Rohatgi, USA
      • Notch - Noemi Reguart, Spain
  • Upcoming Therapeutics: Preclinical to Clinical - Biao He, USA
  • Lung Cancer Stem Cells and Their Application to Future Prevention Research - John Minna, USA
   
Mesothelioma
E12 Pleural Mesothelioma : Bridging the Present with the Future
  Chairs:Hedy Kindler, USA; Tuncay Goksel, Turkey
 
  • Biomarkers: What Do We Know and How Do We Use Them? - Bruce Robinson, Australia
  • What is the Standard Treatment of MPM? First and Second Line - Paul Baas, Netherlands
  • The Challenges of New Drug Development for Mesothelioma - Hedy Kindler, USA
Cost Effectiveness
E13 Cost Effectiveness of Lung Cancer Care
  Chair: William Evans, Canada; James Bishop, Australia
 
  • Cost Studies in Lung Cancer-What’s the Purpose? - James Bishop, Australia
  • The Use, Cost and Cost-Effectiveness of Chemotherapy in NSCLC -  Scott Ramsey, USA
  • Molecular Targeted Therapy – Can We Afford It? - William Evans, Canada
Pathology
M18 Adenocarcinoma: Multidisciplinary Classification
  Chairs: Masayuki Noguchi, Japan; Kirk Jones, USA
 
  • The New IASLC/ATS/ERS International Multidisciplinary Lung Adenocarcinoma Classification - William Travis, USA
  • Compartment Concept for Lung Cancer Pathogenesis - Ignacio Wistuba, USA
  • Expression profiling-based approaches for a better understanding of human lung cancer biology - Takashi Takahashi, Japan
  • In Situ, Invasion, Extension as Prognostic Factors in adenocarcinoma - Masayuki Noguchi, Japan
Supportive Care
M19 Bringing Quality of Life Assessment into the Mainstream of Lung Cancer Management
  Chairs: Natasha Leighl, Canada; Jin Soo Lee, South Korea
 
  • Which Tool of Measurement? - Peter Harper, UK
  • Defining Clinically Relevant Changes in QOL Measurements -  David Cella, USA
  • Improving Compliance in QOL Measurement With Web-Based Tools -  James Rigas, USA
  • Long-term QOL Following Surgery for NSCLC -Pierre Theodore, USA
Surgery
E14 Emerging Options for Therapy in Early Stage NSCLC
  Chairs: Jasleen Kukreja, USA; Hiromi Wada, Japan
 
  • Current status of Stereotactic Body Radiation Therapy (SBRT) - Yasushi Nagata, Japan
  • Radiofrequency Ablation - Hiran Fernando, USA
  • Stage Specific Therapy for NSCLC:Choosing the right operation - Mark Krasna, USA
Prevention
E15 Chemoprevention: Past, Present, Future
  Chairs: Desmond Carney, Ireland; Edward Kim, USA
 
  • Chemoprevention in the 21st Century - Edward Kim, USA
  • High Throughput Screening and the Selection of Natural Compounds for Prevention - Haian Fu, USA
  • Transgenic Mouse Models as Tools for Lung Cancer Chemoprevention - Ethan Dmitrovsky, USA
Advocacy
M20 Advocacy and Survivorship in Lung Cancer
  Chairs: Selma Schimmel, USA; Bonnie Addario, USA
 
  • National Lung Cancer Partnership : The US Approach - Joan Schiller, USA
  • Lung Cancer Advocacy - The European Appraoch - Jesme Fox, UK
  • Lung Cancer Alliance: How to Succeed in Increasing the Awareness about Lung Cancer - Laurie Fenton-Ambrose, USA
  • Bonnie J. Addario Lung Cancer Foundation: Bridging to the Future - Bonnie Addario,USA
  • The Role of Media in Increasing the Awareness About Lung Cancer –  John Seng, USA
Radiation Oncology
M21 Implementing Radiation and Systemic Therapy for Stage III Non-Small Cell Lung Cancers
  Chairs: Paul Van Houtte, Belgium; Walter Curran, USA
 
  • What Should be the Standard of Care Outside Clinical Trials? - Walter Curran, USA
  • Radiation Volume Considerations in Combined Modality Therapy - Laurie Gaspar, USA
  • When is Concurrent Chemo-Radiation Not the Treatment of Choice in Inoperable Stage III Disease? - Fergus Macbeth, UK
  • Integration of Novel Targeted Therapy to Combined Chemoradiation – What Agent and What Settings? - Quynh-Thu Le, USA
   
12:15 - 14:15 Satellite Symposia supported by an educational grant from Genentech BioOncology & OSI Oncology:
  Integration of Tissue Biomarker Assays into Protocol and Non-protocol Management of Lung Cancer
   
12:15 - 14:15 POSTER DISPLAY / AUTHOR STAND BY TIME
   
14:30 – 16:00    PROFFERED PAPER AND POSTER DISCUSSION SESSIONS
  Proffered Paper Sessions (pdf) updated 16 July
  Poster Discussion Sessions (pdf) updated 16 July
   
16:30 – 18:00    INTERACTIVE GRAND ROUNDS SESSION
GR4 Debate: Monoclonal Antibodies versus Tyrosine Kinsase Inhibitors: Pros and Cons
  Chairs: Michael Boyer, Australia; Frank Griesinger, Germany
  Participants: Michael Boyer (Monoclonal Antibodies), Australia; Ron Natale (TKI’s), USA
   
16:30 – 18:00    EDUCATION AND MINI SYMPOSIA SESSIONS
Medical Oncology
M22 Open Challenges in the Management of Advanced NSCLC
  Chairs:  Kosta Syrigos, Greece; Edward Kim, USA
 
  • Mechanisms of Drug Resistance with Cytotoxics  – Miquel Taron, Spain
  • Maintenance With Cytotoxics  – Karen Kelly, USA
  • Maintenance with EGFR Agent - Jacek Jassem, Poland
  • Maintenance with VEGF Agent - Roy Herbst, USA
  • Role of Radiotherapy in the Management of Metastatic Disease - Dirk De Ruysscher, Netherlands
M23 SCLC : An Orphan Disease?
  Chairs: Bonnie Glisson, USA; Pieter Postmus, Netherlands
 
  • Epidemiology of SCLC - Ramaswamy Govindan, USA
  • Small Cell Lung Cancer : Current Standards – Kaoru Kubota, Japan
  • Targeted Therapies : The Available Evidence  - Bruce Johnson, USA
  • Novel systemic therapies for small cell lung cancer  - Charles Rudin, USA
Pulmonary
M24 The Role of the Chest Physician in a Multidisciplinary Lung Cancer Clinic
  Chairs: James Jett, USA; Pyng Lee, Singapore
 
  • Differential Diagnoses - Kazuma Kishi, Japan
  • PET For Diagnosis and Staging - Johan Vansteenkiste, Belgium
  • Preoperative Evaluation of Pulmonary Function - Kwun Fong, Australia
  • Pulmonary Complications in the Treatment of Lung Cancer - Julien Mazieres, France
  • Interventional Bronchoscopy - Pyng Lee, Singapore
Biology
M25 Lung Cancer Biomarkers
  Chairs:  John Field, UK; Lorriana Leard, USA
 
  • Lung Carcinogenesis Detected by Exhaled Breath Approaches - Simon Spivack, USA
  • Novel Genomic Applications in Lung Cancer: What Are The Latest SNPs and CHIPs? - Mark Geraci, USA
  • Development of Gene Methylation as a Biomarker for Lung Cancer Detection - Steven Belinsky, USA
  • Proteomics - Pierre Massion, USA
  • Plasma DNA as a Biomarker for Lung Cancer Detection and Prognosis - Gabriella Sozzi, Itlay
M26 Molecular Predictors of Response and Resistance to EGFR Tyrosine Kinsase Inhibitors (TKI’s)
  Chairs: Vincent Miller, USA; Tony Mok, Hong Kong
 
  • EGFR AND KRAS mutations in lung adenocarcinomas: Two contrasting and mutually exclusive mechanisms for pathogenesis -Tetsuya Mitsudomi, Japan
  • Resistance Factors to EGFR TKIs - William Pao, USA
  • Second-Generation EGFR Inhibitors and Combinations - Ulrich Gatzemeier, Germany
  • Prediction of Benefit from EGFR TKIs by Proteomic Analysis of Pre-treatment Serum - David Carbone, USA
  • EGFR Immunohistochemistry: Prediction of Benefit from Gefitinib - Federico Cappuzzo, Italy
M27 Emerging Fields of Lung Cancer Research
  Chairs: Ryosuke Tsuchiya, Japan; Lisa Coussens, USA
 
  • New Gene Signatures - David Jablons, USA
  • Cyclooxzgenase-2 in Lung Cancer – Karen Reckamp, USA
  • Advances in Mouse Models of Lung Cancer - Ilona Linnoila, USA
  • Isolation and expansion of the tumorigenic lung cancer stem cell population - Ruggero De Maria, Italy
Surgery
M28 Locally Advanced Lung Cancer: Role of Surgery & Mediastinal Evaluation
  Chairs: Wilfried Eberhardt, Germany; Royce Calhoun, USA
 
  • What is the Definition of “Resectable N2 Disease”?- Surgeon’s View - Walter Weder, Switzerland
  • What is the Definition of “Resectable N2 disease”?-Medical Oncologist’s View - Wilfred Eberhardt, Germany
  • Role of Pneumonectomy in the Management of Resectable Non-Small Cell Lung - Rodney Landreneau, USA
  • Surgical Complications for Pre-Operative Therapy -Dominique Grunenwald, France
M29 Specialized Surgical Expertise: Indications, Results
  Chairs: Douglas Mathisen, USA; Stephen Swisher, USA
 
  • Vascular Sleeve Resections -Shaf Kehsavjee, Canada
  • Involvement of the T-spine, including Pancoast Tumor - Garret Walsh, USA
  • Guidelines for Intraoperative Lymph Node Staging - Bernward Passlick, Germany
  • Extent of surgery for synchronous/metachronous pulmonary lesions: Prognostic Implications and Importance of CT Appearance in the Decision Making - Hisao Asamura, Japan
Prevention
M30 Novel Agents in Clinical Trials for Prevention
  Chairs: Robert Keith, USA; Masahiro Fukuoka, Japan
 
  • Oral Iloprost for the Chemoprevention of Lung Cancer - Robert Keith, USA
  • Targeting mTOR for lung cancer prevention - Philip Dennis, USA
  • Zileuton - Omer Kucuk, USA
  • New Avenues for Chemoprevention - Steven Dubinett, USA
E16 Modeling Approaches to Mortality Reduction
  Chair: James Mulshine, USA; Claudia Henschke, USA
 
  • Expectation of Potential Outcomes with "Best Practice" Screening - Claudia Henschke, USA
  • Outcome Measures in the National Lung Screening Trial - Ugo Pastorino, Italy
  • Defining the "High Risk Cohort " for Lung Cancer Screening - Rob J. Van Klaveren, Netherlands
Radiation Oncology
M31 Debate –Role of Adjuvant Radiation Therapy in Resected N2 Non-Small Cell Lung Cancer Patients
  Chairs: Umberto Ricardi, Italy; Cecile Le Pechoux, France
 
  • Pro: Francoise Mornex, France
  • Con:  Noah Choi, USA
Imaging
E17 Image Guided Procedures
  Chairs:  Robert Kerlan, USA; Jeremy Erasmus, USA
 
  • Percutaneous Biopsies - Elizabeth Moore, USA
  • Radiofrequency Ablation - Robert Suh, USA
  • Stenting and Embolization - Robert Kerlan, USA
   
18:30 - 20:30 Educational Concepts Group Satellite Symposium:
  Achieving Lung Cancer Therapy Goals: How should we measure effectiveness

 

MONDAY 3 AUGUST

07:00 - 08:00 "Destigmatizing Lung Cancer: Developing a Road Map for the Future - A Think-Tank Presentation" sponsored by UT Southwestern Medical Center & the National Lung Cancer Partnership
07:00 - 08:00 CME Outfitters Satellite Symposium:
  Individualizing Treatments for the Thoracic Malignancies
07:00 - 08:00 The Center for Biomedical Continuing Education Satellite Symposium:
  Immunotherapy for the Treatment of Non-Small Cell Lung Cancer
   
07:00 – 08:00    MEET THE PROFESSOR SESSIONS
Medical Oncology
MTP22 Management of Thymoma. – Tracey Evans, USA
MTP23 Special Populations: Elderly:Cesare Gridelli, Italy and PS2: - Rogerio Lilenbaum, USA
Pulmonary
MTP24 Evaluation of Solitary Pulmonary Nodules - David Midthun, USA
MTP25 Bronchial Intraepithelial Neoplasia and Early Central Airway Lung Cancer: Screening,Diagnosis and Treatment.-  Rex Yung, USA
Biology
MTP26 Gene Therapy in Lung Cancer - Jack Roth, USA
Mesothelioma
MTP27 The Extended Debate on Surgery
  Chair: Valerie Rusch, USA
 
  • Surgery in Mesothelioma: YES - David Sugarbaker, USA
  • Surgery in Mesothelioma: NO - Nick Pavlakis, Australia
Pathology
MTP28 Preneoplastic Lesions - Andrew Nicholson, UK
Supportive Care
MTP29 Comprehensive Supportive Care in the Patient with Mesothelioma - Helen Clayson, UK
Radiation Oncology/Surgery
MTP30 The role of radiotherapy in patients with mesothelioma: - Allan Price, Thymic Tumors: Where is the Evidence? - Robert Cameron, USA
Imaging
MTP31 Image Guidance in Judging Therapeutic Response - David Shelton, USA
   
08:30 – 10:00    PRESIDENTIAL SYMPOSIUM
PRS Presidential Address and Selected Proffered Papers
  Chairs: Nagahiro Saijo, Japan; David Jablons, USA
 
  • State of the IASLC - Nagahiro Saijo, Japan
  • Mutations and copy number gains of KRAS gene correlate with biological activity of ras and clinical outcome in lung adenocarcinomas - Junichi Soh, University of Texas Southwestern Medical Center at Dallas, USA
    Discussant: Tetsuya Mitsudomi, Japan
  • Evolution of gene expression and biological pathways involved at successive steps of lung squamous carcinogenesis - Celine Mascaux, Institut Jules Bordet, ULB, Belgium
    Discussant: John Minna, USA
  • A phase III randomized trial of surgery (S) alone, or preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early stage non-small cell lung cancer (NSCLC): NATCH follow-up data - Enriqueta Felip, Vall d'Hebron University Hospital, Spain
    Discussant: David Jablons, USA
  • A Randomized Phase III Study of Gefitinib (IRESSATM) versus Standard Chemotherapy (Gemcitabine plus Cisplatin) as a First-line Treatment for Never-smokers with Advanced or Metastatic Adenocarcinoma of the Lung - Jin Soo Lee, National Cancer Center Korea, Korea
    Discussant: Frances Shepherd, Canada
   
09:30 - 13:00 POSTER DISPLAY (P3 will be displayed on Monday and Tuesday)
P3

Combined Modality Therapy
Early Detection and Chemoprevention
Oncology Nursing
Pathology
Patient Advocacy
Prognostic and Predictive Markers
Radiotherapy
Supportive and Palliative Care

Poster Presentations (pdf) updated 16 July

   
10:00 - 10:30 POSTER DISPLAY / AUTHOR STAND BY TIME
   
10:30 – 12:00    INTERACTIVE GRAND ROUNDS SESSION
GR5 Therapy for Early Stage NSCLC with Poor Lung Function: Surgical vs. Non-Surgical
  Participants: Brachytherapy - Yuko Nakayama, Japan; Stereotactic Radiotherapy Early Stage NSCLC with Poor Lung Function - Suresh Senan, Netherlands; Surgery - Royce Calhoun, USA
   
10:30 – 12:00    HIGHLIGHT OF THE DAY SESSION
HOD2 HIGHLIGHT OF THE DAY
 
  • Medical and Radiation Oncology - Nevin Murray, Canada
  • Surgery - David Cooke, USA
  • Pathology - Kirk Jones, USA
  • Mesothelioma - Hedy Kindler, USA
   
10:30 – 12:00    PROFFERED PAPER AND POSTER DISCUSSION SESSIONS
  Proffered Paper Sessions (pdf) updated 16 July
  Poster Discussion Sessions (pdf) updated 16 July
   
12:15 – 12:45    IASLC BUSINESS MEETING
   
12:45 – 18:00    AFTERNOON SOCIAL EXCURSION
 
20:00 – 22:30    GALA RECEPTION

 

TUESDAY 4 AUGUST

07:00 – 08:00    MEET THE PROFESSOR SESSIONS
Medical Oncology
MTP32 Ethnic Differences in Chemotherapy Toxicities and Outcomes - Alex Yuang-Chi Chang, Singapore
MTP33 Mechanisms of Drug Resistance to Targeted Agents -Pasi Janne, USA
MTP34 Limited Surgical Resection and Local Radiation Therapy for High Risk NSCLC - Jeffrey Bogart, USA
MTP35 Ethnic Considerations in EGFR Biology and Clinical Parameters -  Keunchil Park, South Korea
Surgery
MTP36 Emerging Endoscopic Staging Techniques - Todd Demmy, USA
Radiation Oncology
MTP37 Proton Beam Radiotherapy - James Cox, USA
Pulmonary
MTP38 Physiologic Evaluation of Patients with Lung Cancer for Lung Resection - David Cooke, USA
Biology
MTP39 Clinical Implications of the New Staging System: Pulmonary Perspective and Oncology Perspective - Pieter Postmus, Netherlands (Pulmonary); Sarita Dubey, USA (Oncology)
Pathology
MTP40 Mediastinal Tumors - Cesar Moran, USA
MTP41 Should Treatment of NSCLC be Histology-Based? - Lawrence Einhorn, USA
   
07:00 - 08:30 WORKSHOP ONEGFR BIOMARKERS: METHODOLOGY STANDARDIZATION
   
08:30 – 10:00    PLENARY SESSION
PL3 Implementation of IASLC Revised Staging System
  Chairs:  Desmond Carney, Ireland; Valerie Rusch, USA
 
  • Overview Peter Goldstraw, UK
  • Pathologic Implications - Elisabeth Brambilla, France
  • Imaging Implications – Edward Patz, USA
  • Taking the New Staging System into the Clinic – Valerie Rusch, USA
   
09:30 - 13:00 POSTER DISPLAY (P3 will be displayed on Monday and Tuesday)
P3

Combined Modality Therapy
Early Detection and Chemoprevention
Oncology Nursing
Pathology
Patient Advocacy
Prognostic and Predictive Markers
Radiotherapy
Supportive and Palliative Care

Poster Presentations (pdf) updated 16 July

   
12:00 - 12:30 POSTER DISPLAY / AUTHOR STAND BY TIME
 
10:30 – 12:00    INTERACTIVE GRAND ROUNDS SESSION
GR6 Pre-operative vs. Post-operative Chemotherapy for Early Stage NSCLC
  Chair: Katherine Pisters, USA
Participants: Induction chemotherapy for operable Non-Small Cell Lung Cancer - Thierry Le Chevalier, UK; Post-Operative Therapy - Jin Soo Lee, South Korea
   
10:30 – 12:00    HIGHLIGHT OF THE DAY SESSION
HOD3 HIGHLIGHT OF THE DAY
 
  • NSCLC Advanced Disease & Imaging - Michael Cullen, UK
  • Basic Science & Translational Research - Sanjay Popat, UK
  • Surgery - Masahiro Tsuboi, Japan
  • Combined Modality Therapy - Francoise Mornex, France
   
10:30 – 12:00    EDUCATION AND MINI SYMPOSIA SESSIONS
Medical Oncology
E18 Adjuvant Therapies in Early Disease Management
  Chairs: Heather Wakelee, USA; Harubumi Kato, Japan
 
  • Systemic Chemotherapy : The Current Evidence  - Howard “Jack” West, USA
  • Is There Still a Role for Adjuvant Radiotherapy? - Rodrigo Arriagada, France
  • Vaccine as Adjuvant Treatment for Non-Small Cell Lung Cancer (NSCLC) – Charles  Butts, Canada
  • Antifolate in the Adjuvant Setting - Yukito Ichinose, Japan
M32 Supportive Care Optimization as a Target
  Chairs: Peter Harper, UK; Paul Hesketh, USA
 
  • Optimizing Supportive Care in Lung Cancer: Recent Advances in Antiemetics - Paul Hesketh, USA
  • Evaluations of Symptoms and Quality of Live in Patients with Lung Cancer - Richard Gralla, USA
  • Anemia - Corey Langer, USA
  • Bone Metastases - Carlo Barrios, Brazil
  • Dyspnea: Evaluation and Management Strategies - Lorriana Leard, USA
Pulmonary
E19 Image Guided Biopsy/ Novel Technologies
  Chairs: Armin Ernst, USA; Eric Edell, USA
 
  • Virtual Bronchoscopic Navigation - Fumihiro Asano, Japan
  • Electromagnetic Navigation - Doug Arenberg, USA
  • Endobronchial Ultrasonography for Peripheral Lung Lesions - Noriaki Kurimoto, Japan
  • EBUS-TBNA: A safe and accurate modality for mediastinal staging - Takehiko Fujisawa, Japan
M33 Cutting Edge in OMICS Research for Lung Cancer
  Chairs: Takashi Takahashi, Japan; David Beer, USA
 
  • Oncogene Discovery in Lung Adenocarcinoma - Matthew Meyerson, USA
  • Proteomics - David Carbone, USA
  • MicroRNA Signatures for Outcome Prediction of Lung Cancer Patients - Pan-Chyr Yang, Taiwan
  • Genomic Signatures -  Anil Potti, USA
  • Gene Expression in the Airways - Avrum Spira, USA
Biology
M34 Signal Transduction Inhibitors – Biology and Activity
  Chairs: Ronald Natale, USA; Daniel Karp, USA
 
  • Signal Transduction Overview - Paul Bunn Jr., USA
  • C-Met Inhibitors - Ravi Salgia, USA
  • Src Inhibitors - Oliver Gautschi, Switzerland
  • MEK Inhibitors - Alex Adjei, USA
  • IGF-1R Inhibitors - Luis Paz-Ares, Spain
Pathology
M35 Lights and Shadows in the Staging of Lung Cancer
  Chairs: Pieter Postmus, Netherlands; Peter Goldstraw, UK
 
  • Lung Cancer Staging: Latest Revision - Frank Detterbeck, USA
  • How New Staging Affects Surgical Perspectives - Ramon Rami-Porta, Spain
  • Pleural Invasion - Victor Roggli, USA
  • Multiple Tumor Nodules: characteristics of lung cancers with multiple nodules from BAC to ALK fusion gene carcinoma - Yuichi Ishikawa, Japan
Supportive Care
M36 Update on Hematopoietic Growth Factors in Lung Cancer Management
  Chairs:  Jan Van Meerbeeck, Belgium; Vera Hirsh, Canada
 
  • Clinical Use of the Erythropoietin Stimulating Agents: Defining the Benefits - Robert Pirker, Austria
  • Clinical Use of the Erythropoietin Stimulating Agents: Defining the Risks -  Paris Kosmidis, Greece
  • Role of Myeloid Growth Factors in Lung Cancer - Jeffrey Crawford, USA
Surgery
E20 Mediastinal Restaging
  Chairs:  Yi-Long Wu, China; Antonio Torres Garcia, Spain
 
  • Imaging of the Mediastinum after Induction Therapy - Paul De Leyn, Belgium
  • EBUS with or without EUS - Mark Krasnik, Denmark
  • Repeat Mediastinoscopy -  Laureano Molins, Spain
Prevention
M37 Risk Stratified Approaches to Prevention of Lung Cancer
  Chairs: Nico Van Zandwijk, Australia; Margaret Spitz, USA
 
  • Chemoprevention of High Risk Patient Populations - Nico Van Zandwijk, Australia
  • Development of Molecular Risk Models for Lung Cancer - Margaret Spitz, USA
  • Convergence Between Adjuvant and Prevention Approaches - Scott Lippman, USA
  • Gene Promoter Methylation as a Biomarker to Assess Selenium Chemoprevention for Lung Cancer - Steven Belinsky, USA
Radiation Oncology
M38 Implementing Image Guided Radiation Therapy in Clinical Practice
  Chairs: Paul Keall, USA; Hiroshi Onishi, Japan
 
  • The Role of PET Imaging for Radiation Treatment Planning and Adaptive Radiation Therapy - Feng-Ming Kong, USA  
  • Pitfalls of Motion Management Strategies in 4-D Radiation Therapy - William Loo, USA
  • IMRT for lung cancer:Good or Bad - Ritsuko Komaki, USA  
  • The Status of Particle Beam Therapy for Lung Cancer - Hirohiko Tsujii, Japan
  • Beyond IGRT- A Look To The Future - Maria Werner Wasik, USA  
Biology
M39 Molecular Epidemiology of Lung Cancer
  Chairs: Christine Ambrosone, USA; Kathy Albain, USA
 
  • Overview: Molecular Epidemiology of Lung Cancer - Christine Ambrosone, USA
  • Biomarkers of Polycyclic Aromatic Hydrocarbon - DNA Damage and Cigarette Smoke Exposure - Regina Santella, USA
  • Role of EGFR pathway activation in Never Smoking Patients with Lung Cancer - Philip Mack, USA
  • Polymorphisms of DNA Repair Genes and Tobacco-related Carcinogenesis - David Christiani, USA
Biostatistics
M40 Statistical Designs in the Bioinformatics Age
  Chairs: Benny Chung-Ying Zee, China; Satoshi Teramukai, Japan
 
  • Adaptive Designs Based on Biomarkers - Jack Lee, USA
  • Phase III Trial Designs for Targeted Agents - Mary Redman, USA
  • A Clinical  Researcher's Perspective - Hideo Kunitoh, Japan
   
12:30 – 14:00    PROFFERED PAPERS AND POSTER DISCUSSION SESSIONS
  Proffered Paper Sessions (pdf) updated 16 July
  Poster Discussion Sessions (pdf) updated 16 July
   
14:00 CONFERENCE ADJOURN